KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Buildings (2016 - 2025)

Abbott Laboratories' Buildings history spans 17 years, with the latest figure at $4.5 billion for Q4 2025.

  • For Q4 2025, Buildings rose 7.99% year-over-year to $4.5 billion; the TTM value through Dec 2025 reached $4.5 billion, up 7.99%, while the annual FY2025 figure was $4.5 billion, 7.99% up from the prior year.
  • Buildings for Q4 2025 was $4.5 billion at Abbott Laboratories, up from $4.2 billion in the prior quarter.
  • Across five years, Buildings topped out at $4.5 billion in Q4 2025 and bottomed at $4.0 billion in Q4 2021.
  • The 5-year median for Buildings is $4.2 billion (2023), against an average of $4.2 billion.
  • The largest annual shift saw Buildings dropped 0.17% in 2021 before it grew 7.99% in 2025.
  • A 5-year view of Buildings shows it stood at $4.0 billion in 2021, then rose by 1.15% to $4.1 billion in 2022, then rose by 2.66% to $4.2 billion in 2023, then grew by 1.11% to $4.2 billion in 2024, then rose by 7.99% to $4.5 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Buildings are $4.5 billion (Q4 2025), $4.2 billion (Q4 2024), and $4.2 billion (Q4 2023).